In a recent bid Ironwood Pharmaceuticals Inc. [IRWD] faced a contemporary bid of $12.04 yielding a -0.43% decline where 2.37 million shares have exchanged hands over the last week. IRWD amount got a boost by 3.97% or $0.46 versus $11.58 at the end of the prior session. This change led market cap to move at 1.82B, putting the price 50.69% below the 52-week high and -14.61% above the 52-week low. The company’s stock has a normal trading capacity of 2.37 million shares while the relative volume is 2.16.
On 3, December 2020, Ironwood Pharmaceuticals Appoints Jay P. Shepard to Board of Directors. According to news published on Yahoo Finance, Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced the appointment of Jay P. Shepard to its Board of Directors, effective immediately. Mr. Shepard will also serve as a member of the Audit Committee. Following the appointment of Mr. Shepard, the Board is now composed of 11 directors, nine of whom are independent.
Analyst Birdseye View:
The most recent analyst activity for Ironwood Pharmaceuticals Inc. [NASDAQ:IRWD] stock was on June 17, 2020, when it was Initiated with an Outperform rating from Northland Capital, which also raised its 12-month price target on the stock to $14. Before that, on September 30, 2020, Wells Fargo Recapitulated an Equal weight rating and elevated its amount target to $9. On July 10, 2019, Credit Suisse Resumed a Neutral rating. On March 27, 2019, Morgan Stanley Upgrade an Equal-weight rating. On February 25, 2019, H.C. Wainwright Upgrade a Neutral rating and increased its price target to $14. On January 24, 2019, JP Morgan Upgrade a Neutral rating. On November 07, 2018, JP Morgan Downgrade an Underweight rating.
In the past 52 weeks of trading, this stock has oscillated between a low of $7.99 and a peak of $14.10. Right now, according to Wall Street analyst the average 12-month amount target is $11.33. At the most recent market close, shares of Ironwood Pharmaceuticals Inc. [NASDAQ:IRWD] were valued at $12.04. According to the average price forecast, investors can expect a potential return of 1.48%.
Ironwood Pharmaceuticals Inc. [NASDAQ:IRWD] most recently reported quarterly sales of 103.47 billion, which represented growth of -21.10%. This publicly-traded organization’s revenue is $1,351,461 per employee, while its income is $185,940 per employee. This company’s Gross Margin is currently 96.70%, its Operating Margin is 35.40%, its Pretax Margin is +13.76, and its Net Margin is +13.76.
If looking now at the Principal structure of this organization, it shows its whole liability to the whole Principal at 127.59 and the whole liability to whole assets at 107.07. It shows enduring liability to the whole principal at 127.25 and enduring liability to assets at 1.07 while looking for an extended time period.
Readers are usually of view to make a close observation to the indicators that support and make resistance before moving to any particular stock. As of now, the company’s stock is sitting at 11.49 points at 1st support level, the second support level is making up to 11.39. But as of 1st resistance point, this stock is sitting at 11.71 and at 11.83 for 2nd resistance point.
Ironwood Pharmaceuticals Inc. [IRWD] reported its earnings at $0.23 per share in the fiscal quarter closing of 9/29/2020. The Analysts for Wall Street were expecting to report its earnings at $0.15/share signifying the difference of 0.08 and 53.30% surprise value. Comparing the previous quarter ending of 6/29/2020, the stated earnings were $0.16 calling estimates for $0.09/share with the difference of 0.07 depicting the surprise of 77.80%.
Important Ratio’s To Watch
Meanwhile, turning our focus to liquidity, the Current Ratio for Ironwood Pharmaceuticals Inc. [NASDAQ:IRWD] is 13.20. Likewise, the Quick ratio is also the same, showing Cash ratio at 4.36. Now if looking for a valuation of this stock’s amount to sales ratio it’s 4.85 and showing 16.59 of P/E (TTM) ratio.
The most recent insider trade was by MacDonald Kelly, Chief Accounting Officer, and it was the sale of 3561.0 shares on Nov 11. Kilroy Conor, the SVP, GC & Secretary, completed a sale of 836.0 shares on Nov 09. On Nov 09, Consylman Gina, SVP, CFO & Treasurer, completed a sale of 1415.0 shares.